("MaxCyte" or the "Company")
Appointment of Joint Corporate Broker
Gaithersburg, Maryland - 3 February 2021: MaxCyte (LSE: MXCT, MXCL), a global cell-engineering and life sciences company, announces the appointment of Stifel Nicolaus Europe Limited as the Company's Joint Corporate Broker with immediate effect alongside existing Joint Corporate Brokers Panmure Gordon and Numis.
MaxCyte is a world-leading provider of cell-engineering enabling technology and is responsible for helping to bring next-generation cell and gene-editing therapies to life. The Company's technology is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 140 cell therapy programmes, with more than 100 licensed for clinical use, and the Company has now entered into twelve clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.